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Introduction
Chronic kidney disease (CKD) is a serious chronic condi-
tion associated with high rates of morbidity, use of com-
plex medication regimens, and poor overall survival, all 
of which contribute to high costs of care.1–3 In 2014, 
expenditures exceeded $50 billion for Medicare benefi-
ciaries with CKD—representing 20% of all Medicare 
spending in beneficiaries >65 years of age.4 Other chronic 
conditions such as hypertension, dyslipidemia, diabetes 
mellitus, and mood disorders are often inadequately man-
aged in this high-risk population.5,6 Reflecting a high 
comorbidity burden, patients with CKD use more medica-
tions than patients without CKD and frequently have 
complex medication regimens.7 Previous studies have 
reported that the number of medications taken by patients 
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Abstract
Objectives: The aims of this secondary analysis were to: (a) characterize medication use following hospital discharge 
for patients with chronic kidney disease (CKD), and (b) investigate relationships of medication use with the primary 
composite outcome of acute care utilization 90 days after hospitalization.
Methods: The CKD-Medication Intervention Trial (CKD-MIT) enrolled acutely ill hospitalized patients with CKD 
stages 3–5 not dialyzed (CKD 3–5 ND). In this post hoc analysis, data for medication use were characterized, and the 
relationship of medication use with the primary outcome was evaluated using Cox proportional hazards models.
Results: Participants were taking a mean of 12.6 (standard deviation=5.1) medications, including medications from a 
wide variety of medication classes. Nearly half of study participants were taking angiotensin-converting enzyme (ACE) 
inhibitors or angiotensin II receptor blockers (ARB). ACE inhibitor/ARB use was associated with decreased risk of the 
primary outcome (hazard ratio=0.51; 95% confidence interval 0.28–0.95; p=0.03) after adjustment for baseline estimated 
glomerular filtration rate, age, sex, race, blood pressure, albuminuria, and potential nephrotoxin use.
Conclusions: A large number, variety, and complexity of medications were used by hospitalized patients with CKD 3–5 
ND. ACE inhibitor or ARB use at hospital discharge was associated with a decreased risk of 90-day acute care utilization.
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with CKD ranges widely from 1 to 38 medications.7–9 
Two recent reports of medication utilization in patients 
with CKD reported a mean of eight medications taken per 
participant. As expected, with increased regimen com-
plexity, the potential for medication-related adverse 
events and adherence difficulties increases.10,11
Hospitalization is a common occurrence in CKD. 
Compared to Medicare beneficiaries without CKD, those 
with CKD stages 3–5 not dialyzed (CKD 3-5 ND) have 
three- to fivefold higher rates of hospitalization (200 vs. 
600–1000 admissions per 1000 patient years, respectively).4 
They are also more likely to be re-hospitalized when com-
pared to patients without CKD. Overall readmissions and 
readmissions resulting in death increase in a stepwise fash-
ion with increased CKD severity.12 Risks of medication-
related adverse events are heightened during acute illness 
and hospital admission, and medication changes made dur-
ing the hospital stay may increase the risk of adverse 
events.13,14 Therefore, more complete characterization of 
medication use in hospitalized patients with CKD is needed 
to understand usage patterns better and to identify opportu-
nities to improve care following acute illness.
The study aim was to determine relationships between 
medication use (number of medications taken, medication 
classes used, and medication regimen complexity) and risk 
of hospital readmissions and emergency department and 
urgent care visits for 90 days after hospitalization in 
patients with CKD 3–5 ND.
Methods
Study design
For patients with CKD 3–5 ND, post hoc analyses were con-
ducted with data on medication use at the hospital-to-home 
transition from the CKD-Medication Intervention Trial 
(CKD-MIT; www.clinicaltrials.gov; NCT01459770).15,16 
The CKD-MIT was conducted at Providence Sacred Heart 
Medical Center and Providence Holy Family Hospital in 
Spokane, Washington, between February 2012 and May 
2015. The Providence Institutional Review Board approved 
the CKD-MIT trial. Conduct of the trial adhered to the prin-
ciples set forth by the Declaration of Helsinki. All partici-
pants provided written informed consent prior to study 
participation.
The study design and main results of the trial have been 
reported previously.15,16 Briefly, the CKD-MIT was 
designed to test the impact of a pharmacist-led, in-home 
medication management intervention compared to usual 
care on a primary composite outcome of acute care utiliza-
tion (hospital readmissions and visits to emergency depart-
ments or urgent care centers) for 90 days following hospital 
discharge in adult participants with CKD 3–5 ND. The 
intervention involved assessment and resolution of medica-
tion discrepancies and medication errors during transition 
from hospital to home. Pharmacists additionally assessed 
suitability of medication use based on consideration of par-
ticipants’ kidney function and other comorbidities, with the 
pharmacists recommending medication changes when 
appropriate. Participants enrolled in the CKD-MIT were 
adults (⩾21 years of age) with CKD 3–5 ND identified by 
at least two measures of estimated glomerular filtration rate 
(eGFR) <60 mL/min/1.73 m2 for more than 3 months dur-
ing the year prior to the index hospital admission for acute 
illness. For study eligibility, eGFR was calculated based on 
local laboratory reports of creatinine values. A detailed 
review of prescription and non-prescription medication use 
was conducted at the baseline assessment within 7 days of 
hospital discharge.
Study definitions
Medication data were systematically categorized by a 
pharmacist investigator according to a pre-specified clas-
sification system developed for the CKD-MIT by two 
members of the study team.15,16 For non-prescription med-
ications, over-the-counter (OTC)/herbal medications were 
operationally defined as any medications that could be 
obtained without a prescription regardless of whether the 
participant was instructed to take the product by a health-
care provider. Frequently occurring OTC products (e.g., 
aspirin, vitamin D) were reported individually. OTC/
herbal medications encountered less frequently (e.g., cin-
namon, vitamin C) were placed into a single “other OTC/
herbal” category. While select insulin products can be pur-
chased without a prescription (e.g., regular and isophane 
(NPH) insulins), all insulin products were classified as 
“antihyperglycemic agents.” Medication use was analyzed 
and reported by CKD stage. A single drug category of 
“ACE inhibitor/ARB” was created for renin–angiotensin 
system (RAS) inhibitors. All medication classifications 
were verified by a second pharmacist investigator. Any 
discordance in classification was discussed among a larger 
group of study investigators, inclusive of pharmacists and 
physicians, to reach a consensus. Medication complexity 
scores were calculated by a study pharmacist and validated 
by a second study pharmacist using the Medication 
Regimen Complexity Index (MRCI).10,17–19
Statistical analyses
Descriptive statistics for key demographic variables, num-
ber of medications taken, medication class use by CKD 
3–5 ND stage, and MRCI scores were calculated 
(mean±standard deviation (SD) or n/N and %). 
Associations of the medication use with the primary out-
come of 90-day acute care utilization were evaluated using 
Cox proportional hazards models. The models applied pre-
dictors (total number of medications taken, medication 
classes taken, and MRCI scores) and were adjusted for 
pre-specified covariates within each model (baseline 
eGFR, age, sex, race, blood pressure, albuminuria, and 
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potential nephrotoxin use (nonsteroidal anti-inflammatory 
drugs and/or proton pump inhibitors (PPI)). As some par-
ticipants experienced more than one event during the study 
follow-up period, all Cox proportional hazard models rep-
resent time to first event. All medication classes outlined 
were tested for relationships with the primary outcome 
(Table 2). p-Values <0.05 were considered statistically 
significant. Data analyses and computations were con-
ducted using IBM SPSS Statistics for Windows v25.0 
(IBM Corp., Armonk, NY).
Results
Of 141 participants enrolled in the CKD-MIT, 35% 
(49/141) had CKD stage 3A, 37% (52/141) had CKD stage 
3B, and 28% (40/141) had CKD stage 4/5 ND (Table 1). 
For all CKD stages, the mean age of participants was ⩾67 
years. Most participants were white, although the CKD 
stage 4/5 ND group was composed of a relatively higher 
proportion of non-white participants compared to the CKD 
stage 3A and 3B groups. The majority of participants had 
diabetes and/or hypertension.
Participants in the CKD-MIT were taking a mean of 8.6 
(n=141, SD=3.4) prescription medications when assessed 
in the home within 7 days after hospital discharge. They 
were also taking a mean of 4.0 (SD=3.6) OTC/herbal med-
ications, giving a mean of 12.6 (SD=5.1) total medications 
(Table 2). The mean number of prescription, OTC/herbal, 
and total medications utilized by patients with CKD-ND 
stage 3A, stage 3B, and stage 4/5 was found to be similar. 
When exploring the complexity of medication regimens, 
mean MRCI scores were similar among groups when 
examined by CKD stage (means of 23–25).
The most common medication class utilized in the com-
bined cohort was antihypertensive agents (92% of partici-
pants; 130/141). Nearly half (46%; 65/141) of all participants 
received angiotensin-converting enzyme (ACE) inhibitor/
angiotensin II receptor blocker (ARB), with the highest use 
in earlier CKD stages (59%; 29/141). No participants were 
receiving both an ACE inhibitor and an ARB in combina-
tion. Other commonly used classes were OTC/herbal medi-
cations (74% of participants; 105/141), platelet inhibitors 
(63% of participants; 89/141), statins (61% of participants, 
86/141), gastrointestinal agents (55% of participants; 
77/141), and antihyperglycemic agents (51% of partici-
pants; 72/141). PPIs were taken by 38% of participants 
(53/141) in the combined CKD-MIT, and 33% of partici-
pants (46/141) were receiving opioid agonists.
The primary outcome (acute care use within 90 days of 
hospital discharge) occurred in 43% (60/141) of 
Table 1. Demographic and clinical characteristics of participants in the CKD-MIT by CKD stage.
CKD stage 3A 
(eGFR 45–59  
mL/min/1.73 m2), 
n/N=49/141
CKD Stage 3B 
(eGFR 30–44  
mL/min/1.73 m2), 
n/N=52/141
CKD stage 4/5 
(eGFR 15–29  
mL/min/1.73 m2), 
n/N=40/141




Age (M±SD) 68±11 72±9 67±13 69±11
n % N % n % n %
Sex
 Male 28 57 23 44 23 56 74 52
 Female 21 43 29 56 17 43 67 48
Race
 White 46 94 43 83 30 75 119 84
 Non-white 3 6 9 17 10 25 22 16
Ethnicity
 Hispanic 0 0 3 6 0 0 3 2
 Non-Hispanic 49 100 49 94 40 100 138 98
Diabetes 22 45 31 60 26 65 79 56
Hypertension 43 88 43 83 31 78 117 83
 M SD M SD M SD M SD
Prescription 
medications
8.2 3.8 8.8 3.4 8.9 2.8 8.6 3.4
OTC/herbal 
medications
3.8 3.6 4.1 3.2 4.0 4.1 4.0 3.6
Total medications 12.0 5.5 12.9 4.5 12.9 5.2 12.6 5.1
Total MRCI score 22.8 12.6 23.9 9.8 25.1 9.5 23.9 10.7
CKD: chronic kidney disease; CKD-MIT: CKD-Medication Intervention Trial; eGFR: estimated glomerular filtration rate; M: mean; MRCI: medication 
regimen complexity index; OTC: over-the-counter; SD: standard deviation.
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Table 2. Medication use by class in the CKD-MIT by CKD stage.
Medication class
CKD stage 3A 
(eGFR 45–59  
mL/min/1.73 m2), 
n/N=49/141
CKD stage 3B 
(eGFR 30–44  
mL/min/1.73 m2), 
n/N=52/141
CKD stage 4/5 







n % n % n % n %
Antihypertensive agent 45 92 46 89 39 98 130 92
ACE inhibitor/ARB 29 59 19 37 17 43 65 46
Diuretic 21 43 31 60 31 78 83 59
 Loop 19 39 24 46 28 70 71 50
 Thiazide 4 8 6 12 6 15 16 11
 Potassium sparing 5 10 7 14 2 5 14 10
Beta blocker 21 43 28 54 20 50 69 49
Calcium channel blocker 13 27 13 25 18 45 44 31
 Dihydropyridine 7 14 9 17 16 40 32 23
 Non-dihydropyridine 6 12 5 10 3 8 14 10
Other antihypertensive 0 0 7 14 6 15 13 9
Other OTC/herbal 32 65 41 79 32 80 105 74
Platelet inhibitor 35 71 31 60 23 58 89 63
 Aspirin 33 67 26 50 21 53 80 57
 Other platelet inhibitor 6 12 17 33 6 15 29 21
Statin 29 59 35 67 22 55 86 61
Gastrointestinal agent 27 55 29 56 21 53 77 55
 Proton pump inhibitor (PPI) 17 35 22 42 14 35 53 38
 Other gastrointestinal agent 17 35 15 29 10 25 42 30
Antihyperglycemic agent 18 37 29 56 25 63 72 51
 Insulin 13 27 19 37 21 53 53 38
 Oral antihyperglycemic agent 10 20 16 31 6 15 32 23
 Sulfonylurea 4 8 7 14 5 13 16 11
 Metformin 7 14 6 12 1 3 14 10
 DPP-4 Inhibitor 2 4 2 4 0 0 4 3
 Thiazolidinedione 0 0 2 4 0 0 2 1
 GLP-1 receptor agonist 1 2 1 2 0 0 2 1
Vitamin D 20 41 28 54 24 60 72 51
Psychoactive agents 24 49 28 54 17 43 69 49
 Antidepressant 18 37 20 39 10 25 48 34
 Anticonvulsant 8 16 9 17 5 13 22 16
 Anxiolytic 8 16 4 8 5 13 17 12
 Insomnia medication 3 6 4 8 0 0 7 5
 Other psychoactive agent 1 2 0 0 0 0 1 <1
Opioid agonist 16 33 19 37 11 28 46 33
Acetaminophen 13 27 21 40 10 25 44 31
Thyroid supplement 13 27 13 25 11 28 37 26
Antibiotic agent 15 31 10 19 11 28 36 26
Anticoagulant 11 22 14 27 11 28 36 26
 Warfarin 9 18 11 21 10 25 30 21
 Direct oral anticoagulant 2 4 3 6 0 0 5 4
 Heparin 0 0 0 0 1 3 1 <1
 Low molecular weight heparin 0 0 0 0 1 3 1 <1
Uric acid lowering agent 13 27 9 17 13 33 35 25
Iron supplements 10 20 13 25 11 28 34 24
Nitrate 10 20 13 25 7 18 30 21
Prescription phosphate binder 0 0 2 4 3 8 12 9
Parkinson’s disease medication 3 6 2 4 1 3 6 4
(Continued)
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Medication class
CKD stage 3A 
(eGFR 45–59  
mL/min/1.73 m2), 
n/N=49/141
CKD stage 3B 
(eGFR 30–44  
mL/min/1.73 m2), 
n/N=52/141
CKD stage 4/5 







n % n % n % n %
NSAID 2 4 3 6 0 0 5 4
Erythropoietin stimulating agent 0 0 1 2 1 3 2 1
Potassium binder 0 0 1 2 0 0 1 <1
Dementia medication 0 0 1 2 0 0 1 <1
Anti-neoplastic 0 0 1 2 0 0 1 <1
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; NSAID: 
nonsteroidal anti-inflammatory drug.
Table 2. (Continued)
Table 3. Cox proportional hazards analyses for ACE 
inhibitor/ARB use with model covariate adjustments for the 
primary outcome (acute care utilization: hospital readmissions 




ACE inhibitor/ARB use 0.52 (0.29–0.94)
Model 2
ACE inhibitor/ARB use 0.53 (0.29–095)
Baseline eGFR 0.99 (0.97–1.01)
Model 3
ACE inhibitor/ARB use 0.47 (0.25–0.86)





ACE inhibitor/ARB use 0.51 (0.28–0.95)




Mean SBP 1.01 (0.99–1.02)
Use of potential nephrotoxic agent† 0.76 (0.42–1.40)
Albuminuria (urine albumin–creatine ratio)  
30–300 mg/g 0.67 (0.28–1.61)
>300 mg/g 1.31 (0.58–2.97)
*Fully adjusted model.
†Use of NSAID and/or PPI.
CI: confidence interval; HR: hazard ratio; SBP: systolic blood pressure.
participants in the CKD-MIT. In total, 37 hospitalizations 
and 30 visits to the emergency department or urgent care 
occurred in the 90-day CKD-MIT follow-up period. The 
three most common diagnoses for hospital readmission 
were: cardiovascular events (30%; 11/37 re-hospitaliza-
tions); gastrointestinal diseases (30%; 11/37), and infec-
tions (27%; 8/37). The most frequent diagnostic categories 
for emergency department urgent care visits were: infec-
tions (27%; 8/30 visits), gastrointestinal diseases (17%; 
5/30 visits), and cardiovascular events (17%; 5/30 visits).16 
Neither MRCI scores nor total number of medications 
taken were related to the primary outcome. Of all medica-
tion classes, ACE inhibitor or ARB use was associated 
with a decreased risk of experiencing the primary outcome 
(hazard ratio=0.51; 95% confidence interval 0.28–0.95; 
p=0.03) in the fully adjusted model (Table 3 and Figure 1). 
ACE inhibitor or ARB dose did not influence the fully 
adjusted model.
Discussion
This analysis of CKD-MIT data provides a comprehensive 
account of medication use during the hospital-to-home 
transition in people with CKD 3–5 ND, a population at high 
risk for adverse drug events and hospital readmissions.12 
Information about medication use was obtained from study 
participants, their family members, and/or caregivers and 
categorized by a CKD-MIT classification algorithm to pro-
vide an accurate account of medications taken. Following 
discharge, participants took more than a dozen medications 
on average, with the most frequently used classes being 
antihypertensive agents, followed by OTC/herbal medica-
tions, antiplatelet agents, and statins. ACE inhibitor or ARB 
use following discharge from hospital was associated with 
a decreased risk of experiencing the primary outcome of 
acute care utilization within 90 days following hospitaliza-
tion. However, the total number of medications and MRCI 
scores did not predict the primary outcome.
Acute care utilization in the first 90 days after hospitali-
zation occurred in 43% (60/141) of participants enrolled in 
the CKD-MIT.16 ACE inhibitors or ARBs were prescribed 
to 46% (65/141) of study participants at hospital discharge. 
This relatively low rate of ACE inhibitor or ARB use could 
be accounted for, at least in part, by the common clinical 
practice of discontinuing RAS inhibitors during acute ill-
ness (“sick days”) because of concerns of acute kidney 
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injury (AKI), hyperkalemia, or hypotension.20 Conversely, 
it is possible that bias by indication for ACE inhibitor or 
ARB use may contribute to the observed favorable effects, 
which should be evaluated in future studies. Nevertheless, 
the risk of 90-day acute care utilization was reduced by 
nearly half in ACE inhibitor or ARB users. A recent study 
reported that medication appropriateness and regimen com-
plexity were not associated with 30- or 90-day hospital 
readmissions, but use of RAS inhibitors was associated with 
reduced occurrence of 30- or 90-day readmissions by about 
half.21 Another study reported that ACE inhibitor or ARB 
use within 6 months following hospital discharge for AKI 
was associated with lower mortality after 2 years.22
Patients re-hospitalized for an adverse drug event were 
reported to take more medications after hospitalization 
compared to those who were not readmitted (11.2 vs. 7.8 
medications, respectively).10 We found that patients with 
CKD were taking more than a dozen medications on aver-
age following hospitalization. However, a relationship 
between the number of medications and risk of acute care 
visits following hospitalization was not detected. A sys-
tematic review reported that outcomes such as hospital 
readmission and medication adherence were significantly 
impacted by higher MRCI scores.23 Patients who were 
readmitted had a mean MRCI of 30 at the index hospitali-
zation discharge compared to an MRCI of 20 for those 
who were not readmitted. Mean calculated MRCI scores in 
this analysis of the CKD-MIT were similar to scores seen 
in those studies. However, one study demonstrated that 
mean MRCI scores for adults with multiple chronic condi-
tions that were calculated based on the hospital discharge 
list were significantly higher than mean MRCI scores that 
were calculated based on participant-reported home medi-
cation use.11 In that study, MRCI scores calculated using 
the hospital discharge list were predictive of hospital read-
mission within 30 days of discharge, whereas MRCI scores 
calculated based on participant-reported medication use 
were not predictive of hospital readmission.11 Similarly, in 
the current analysis, MRCI scores calculated in partici-
pants with CKD based on participant-reported medication 
use did not relate to post-hospitalization use of acute care. 
It is possible the high severity of illness in CKD may have 
subsumed most of the risk.
Another area of heightened interest is the treatment of 
pain and use of psychotropic agents in the CKD popula-
tion. The high rates of opioid (~30% across all groups) and 
psychotropic medication (~50% across all groups) use was 
notable in the CKD-MIT. Pain is a common symptom in 
patients with CKD. Yet, use of pain medication in this pop-
ulation has risks.24–26 Previous reports have suggested psy-
chotropic medication use and co-occurring serious mental 
illness as a potential mediator of increased re-hospitaliza-
tion risk in patients with CKD.27
The findings of this study should be considered within its 
limitations. First, medication use was recorded by inter-
viewing patients and caregivers during a home visit or dur-
ing a visit to the research center within 7 days following 
hospital discharge. Thus, medication use reported in the pre-
sent analysis included short-term medication use after hos-
pitalization and did not account for medications under 
temporary discontinuation. Second, interest in study partici-
pation was likely greater in CKD-aware patients, which 
may introduce selection bias for adherence and other health-
related behaviors. Third, the main diagnoses for which med-
ications were being utilized were not always known, and 
therefore could not be consistently used to determine medi-
cation indication. For example, if a medication such as 
duloxetine was part of a patient’s regimen, it may not be 
apparent whether it was being used to treat depression or 
neuropathy. To avoid inaccurate assumptions concerning 
indications, medications were categorized generally by 
class. Due to the limited sample size, there was insufficient 
power to determine associations of ACE inhibitors or ARBs 
separately. Fourth, confounding variables such as changes 
in laboratory values, types of care (e.g., specialists, in-home 
caregivers), socioeconomic status, and health literacy were 
not available. Overall, these limitations speak to the difficul-
ties of assessing and managing medications in this complex, 
severely ill population. Yet, despite its limitations, the pre-
sent study provides valuable new knowledge about overall 
medication use, as well as observations about possible ben-
efits of RAS inhibitor use in the early post-discharge period 
for hospitalized patients with CKD.
Conclusions
In conclusion, this post hoc analysis of the CKD-MIT high-
lights the large number and variety of medication classes 
Number at Risk
ACE Inhibitor/ARB 65 58 52 44
No ACE Inhibitor/ARB 76 59 45 37
Figure 1. Kaplan–Meier event-free survival for the primary 
outcome (acute care utilization: hospital readmissions and 
emergency department and urgent care visits within 90 days 
after hospitalization) by ACE inhibitor/ARB use in the fully 
adjusted Cox proportional hazards model (N=141). ACE: 
angiotensin-converting enzyme; ARB: angiotensin receptor 
blocker.
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utilized and the complexity of regimens consumed by 
patients in the CKD 3–5 ND population. Notably, ACE 
inhibitor or ARB use at hospital discharge in patients with 
CKD 3–5 ND was associated with a decreased risk of the 
primary outcome of 90-day acute care utilization. This find-
ing warrants further investigation to evaluate for improved 
clinical outcomes by early reinstitution of ACE inhibitor or 
ARB therapy following hospitalization for acute illness.
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